sam\u00aex1
sam\u00aex1

LAS VEGAS, January 26, 2023 (Newswire.com) - ZetrOZ Systems will demonstrate the effectiveness of its sam®x1 and sam®2.0 sustained acoustic medicine devices for soft tissue injury therapies at the Las Vegas Regenerative Medicine and MSK Ultrasound Course, the longest-running medical education seminar of its kind, from Jan. 26 to 28 in Las Vegas.

The sam®x1 is the first FDA-cleared pain management device of its kind cleared for everyday, at-home use, and the sam®2.0 is the long-duration solution. Both are wearable pain relief ultrasound devices that inhibit inflammation and accelerate natural healing by stimulating tissue regeneration, increasing circulation, and nutrient exchange in deep musculoskeletal tissue.

The multiple-day educational course, at the Planet Hollywood Resort and Casino, Las Vegas, welcomes hundreds of practitioners as varied as orthopedic surgeons, sports medicine physicians, PM&R physicians, pain management physicians, interventional radiologists, rheumatologists, physical therapists, naturopathic doctors, chiropractors, podiatrists, physician assistants, nurse practitioners, diagnostic sonographers and more.

"The Las Vegas Regenerative Medicine and MSK Ultrasound Course brings in leading physicians and other practitioners who will speak on the administration of ultrasound technology and its many benefits - it offers patients options beyond pain medication or surgery," says Dr. George Lewis, founder and CEO of ZetrOZ Systems. "We're incredibly excited to attend and bring awareness of our innovative pain relief ultrasound device portfolio to more healthcare professionals."

The first day of the program will be dedicated to reviewing scientific updates, new regulations, and best practices of the orthopedic discipline. The last two days will focus on practical ultrasound operation, and ZetrOZ Systems sam®x1 and sam®2.0 will be joining the lineup of medical treatment options available for clinicians to review and apply.

Backed by more than 30 clinical studies, sam® technology was developed with research funded by the National Institutes of Health and the U.S. Department of Defense with the intent of finding new methods of soft tissue healing that reduce the use of narcotics and invasive treatments.

To learn more about sustained acoustic medicine and its effectiveness in soft tissue healing, visit zetroz.com.

About ZetrOZ Systems

ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents. The exclusive manufacturer and developer of the sam® product line is designed for the treatment of acute and chronic musculoskeletal conditions.

Academic Urology Research Investigators Consortium
AURIC Logo

SARATOGA SPRINGS, N.Y., January 26, 2023 (Newswire.com) - Criterium, Inc., a full-service Contract Research Organization (CRO), is pleased to announce AURIC (Academic Urology Research Investigators Consortium) — a newly formed GU Oncology Consortium. The newest oncology consortia created by Criterium, Inc., it was launched in late July to support advanced oncology clinical research initiatives in translational research for genito-urinary (GU) cancers. This is the 5th specialty oncology consortia managed by Criterium. AURIC will follow in the footsteps of Criterium's other successful Consortia: in GI, Academic GI Cancer Consortium (AGICC); in breast, Academic Breast Cancer Consortium (ABRCC); in thoracic/lung cancers, Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC); and in multiple myeloma, Academic Myeloma Cancer Consortium (AMyC). These consortia are currently comprised of 41 renowned institutions and 73 Key Opinion Leaders in North America.

Directing the new consortium will be Dr. Thomas Flaig, Vice Chancellor of Research for the University of Colorado in Denver at the Anschutz Medical Campus. Dr. Flaig brings his significant clinical and translational research experience to this leadership position, having led both local and national multi-center clinical trials and served as the local principal investigator on a large number of Phase I, II and III studies. He previously served as medical director of the clinical trials office and associate director of clinical research at the CU Cancer Center. Known nationally for his work on bladder cancer, Dr. Flaig has been a member of the National Cancer Institute's Investigational Drug Steering Committee and the bladder cancer task force. He also serves as chair of the bladder cancer committee for the National Comprehensive Care Network. He is excited about the prospect of completing unique and forward-thinking trials from pharmaceutical companies investigating GU indications. His expertise and unique vision for research in the GU indications will create new possibilities for GU therapies and clinical studies that demonstrate important value for pharmaceutical sponsors and the patients who participate in these important trials.

About Criterium Inc.
Criterium is a full-service, global and technology-driven contract research organization that offers a unique mix of high-quality, innovative clinical research solutions for the biopharmaceutical, pharmaceutical, medical device and CRO industries. Visit us online: https://www.criteriuminc.com/  

About the Oncology Consortia of Criterium (OCC)
The Oncology Consortia of Criterium are a collaboration of outstanding Cancer Research Consortia delivering innovative research and unparalleled expertise. The Consortia Model utilizes translational science methodologies to streamline cancer research and development. Each member is usually located at a hospital or research center associated with an academic institution that has superior infrastructure and staff to meet the requirements — not only for translational and investigator-initiated studies, but also design and completion of all phases of clinical trials. Our model allows us to provide expertise and innovative solutions for the rapid design, implementation, and management of complex cancer trials. Visit the Consortia: https://www.criteriuminc.com/oncology-consortia/

SpendMend
SpendMend

GRAND RAPIDS, Mich., January 26, 2023 (Newswire.com) - SpendMend, a leading provider of cost-saving solutions for the healthcare industry, today announced record earnings in 2022, marking their fourth consecutive year of over 30% revenue growth. The company saw a 20% increase in employee count and a healthy increase in clients to over 150 major U.S. health systems, comprising over 3,000 hospitals and facilities. Clients also shared in the good news, enjoying a 32% increase in hard dollar savings delivered to their bottom line as compared to the previous year.

In addition to the strong growth indicators, SpendMend completed several major deals throughout the calendar year of 2022. The company secured a controlling investment from Morgan Stanley Capital Partners ("MSCP"), joined by additional investments from Corewell/Spectrum Health Ventures and Memorial Hermann Health System. 

"For several years, SpendMend has been establishing a new critical segment for the healthcare industry, the Cost-Cycle," states Steve Rodgers, Managing Director and Head of Healthcare at MSCP. "In 2022, we saw accelerated adoption in this growing segment; hospitals and health systems are using SpendMend's emerging cost-cycle platform as an effective strategy to drive significant bottom-line revenue and cost-savings while managing through pricing pressure, supply chain delays, and other lingering effects of the pandemic."

SpendMend, in the past year, expanded its cost-cycle platform through the acquisition of three leading healthcare providers including: VIE Healthcare Consulting, a leading cost consultant for hospitals; Trulla, a next-generation pharmacy procurement platform; and finally, the healthcare division of Moody Associates, P.A., a provider of profit recovery and contract-compliance services. 

Through their innovative suite of cost-cycle solutions, SpendMend helped U.S. healthcare networks to illuminate the "dark data" in their cost-cycle, unlocking trapped dollars and improving operations and overall efficiency. 

"Controlling costs is arguably the biggest challenge facing health systems across the country today," said Scott McLean, Managing Director at Corewell/Spectrum Health Ventures. "Simply put, SpendMend's suite of cost-cycle solutions helps hospitals reduce costs and optimize future savings. SpendMend is a perfect fit for the Corewell/Spectrum portfolio, and they are fast becoming an indispensable partner for U.S. Health Systems."

"For years, we have been guided by a mission to positively impact patient care by delivering value to our clients through our innovative cost-saving solutions," states SpendMend founder and CEO, Dan Geelhoed. "Through that lens, I believe our biggest success from the past year was watching our clients invest the bottom-line benefits of our work back into their patient communities."

About SpendMend 

SpendMend is the leading provider of tech-enabled, cost-savings solutions in the healthcare industry. By combining data, proprietary technology, and analytics with healthcare expertise, SpendMend partners with healthcare networks to expose and improve hidden costs in meaningful ways. The company's mission is to help its clients improve patient care through innovative cost-saving solutions.

WAYNE, Pa., January 26, 2023 (Newswire.com) - McBee®, an industry-leading healthcare services and consulting firm, advised The Care Team (TCT) on the acquisition of 1^st Care Home Health and Care Hospice (1^st Care). 

TCT, a portfolio company of Denver-based private equity firm Revelstoke Capital Partners (Revelstoke), provides hospice, home healthcare including skilled nursing, rehabilitation and therapy services, as well as social workers to patients and families operating across Michigan, Pennsylvania, Texas and Massachusetts. This successful acquisition will accelerate TCT's growing footprint in the Midwest by expanding into Indiana. The addition of 1^st Care aligns with the organization's growth strategy and vision for providing high-quality home care and hospice offerings to its clients.

"We are pleased to partner with the McBee M&A Advisory team as their expertise and industry knowledge continues to guide our strategy as we scale and expand TCT into new states," said Revelstoke Vice President Jonny Miller. "McBee's consulting experts provided us with the insight and data we needed for a successful transaction, and we are pleased to have partnered with McBee on this process."

TCT and Revelstoke engaged McBee for the buy-side clinical due diligence for this transaction, which is TCT's fourth add-on acquisition since partnering with Revelstoke in 2019; McBee provided clinical due diligence support on all four deals. McBee's mergers & acquisition advisory approach included reviewing clinical documentation, compliance, and operational processes to identify potential risk and confirm that 1^st Care met certain regulatory requirements. During the 2022 calendar year, McBee supported clients in completing 28 publicly reported healthcare transactions.

"We would like to congratulate TCT and Revelstoke on their transaction as they continue to expand their footprint," said McBee President Mike Dordick. "Our years of experience and  knowledge of regulatory compliance have positioned McBee as a market leader within healthcare M&A as well as enabled us to advise TCT and Revelstoke on this strategic deal."  

About The Care Team 
The Care Team offers a full spectrum of hospice care and home health services. TCT's hospice team provides specialized care in Michigan, Pennsylvania, Texas and Massachusetts that addresses the patient's physical, emotional, social, and spiritual needs while providing reprieve and comfort for patients' families. TCT Home Health employs experienced industry professionals, including physical therapists, skilled nurses, medical social workers, home health aides, and occupational and speech therapists. For more information, visit www.tctcares.com.

About Revelstoke

Revelstoke (www.revelstokecapital.com) is a private equity firm formed by experienced investors who focus on building industry-leading companies in the healthcare and related business services sectors. Revelstoke partners with entrepreneurs and management teams to execute on a disciplined organic and acquisition growth strategy as it strives to build exceptional companies. Revelstoke is based in Denver, Colorado, and has approximately $5.3 billion of assets under management. Since the firm's inception in 2013, Revelstoke has completed 173 acquisitions, which include 26 platform companies and 147 add-on acquisitions. 

About McBee
McBee® is a recognized leader in providing financial, clinical, and operational strategic advisory services that have addressed the unique needs of more than 3,800 providers across the healthcare industry. Since 1973, McBee has designed services to address challenges and ensure the success of healthcare organizations across the continuum of care by delivering meaningful insights, tailored strategies, and sustainable results. With an average of over 20 years of experience, McBee's consulting professionals have extensive expertise and in-depth knowledge of healthcare regulations and policies. Learn why health systems, physician groups, home health, hospice, long-term care, skilled nursing and other organizations look to McBee for comprehensive healthcare consulting services. 

The Allen Family
Dr. Vinson Eugene Allen and Family

LOS ANGELES, January 25, 2023 (Newswire.com) - The Saint Vinson Eugene Allen Foundation will donate $50,000 to assist special needs families across the country. The program is designed to bring aid to children and families with special disabilities. Dr. Vinson Eugene Allen and his wife, Dr. Connie Yu Allen, foundation founders, named the program Hand-Up in honor of their autistic 9-year-old son. Colin Mathew Allen was featured in a news article in February 2022 for his hard work and generosity to underserved communities.

The Saint Vinson Eugene Allen Foundation has sponsored many families across the nation with free gas cards and has provided the Los Angeles homeless population with free Covid-19 testing. This year, the foundation has created a program that would provide financial relief to parents, caregivers and to those who provide 24-hour care for their child with special needs. Visit the foundation's website to learn more about the mission behind the Hand-Up program and should sign-up to be considered.

Dr. Vinson Eugene Allen States:
"I believe every child, no matter what his or her disability is, deserves the opportunity to succeed in any area he or she chooses. Our top priority is providing relief to those silent heroes that are unselfish, especially when it comes to taking care of children with disabilities." 

Dr. Vinson Eugene Allen is the founder of Dusk to Dawn Urgent Care and Corona Virus Test Los Angeles facilities, located throughout Southern California. For 20 years, Dr. Vinson Eugene Allen and his wife, Dr. Connie Yu Allen, have centered their commitment to servicing Los Angeles County and the surrounding communities. The Saint Vinson Eugene Allen Foundation has been a legendary pillar in the community during tough times. Dr. Vinson Eugene Allen ran as a candidate in the 2022 race for California State Insurance Commissioner in the June primary.

Headquarters

Saint Vinson Eugene Allen Foundation

P.O. Box 10402
Torrance, CA 90505
Website: www.saintvinsoneugeneallen.com
Social Media: @DrAllenLa 
YouTube: Conversations with Dr. Allen
YouTube: AllenFamilyUnity
Website: www.coronavirustestla.com